Biotech Stocks on Investors' Radar -- PDL BioPharma, Progenics Pharma, Agenus, and Aptose Biosciences

NEW YORK, September 12, 2017 /PRNewswire/ --

If you want a Stock Review on PDLI, PGNX, AGEN, or APTO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Monday, September 11, 2017, US markets saw broad based gains with all sectors finishing the trading sessions in green. Major US indices were also bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,432.26, up 1.13%; the Dow Jones Industrial Average edged 1.19% higher, to finish at 22,057.37; and the S&P 500 closed at 2,488.11, up 1.08%. This Tuesday morning, DailyStockTracker.com looks at the performance of these four Biotechnology stocks: PDL BioPharma Inc. (NASDAQ: PDLI), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Agenus Inc. (NASDAQ: AGEN), and Aptose Biosciences Inc. (NASDAQ: APTO). This morning's free research reports on the aforesaid equities can be accessed upon registration on DailyStockTracker.com at: http://dailystocktracker.com/register/

PDL BioPharma 

On Monday, shares in Incline Village, Nevada headquartered PDL BioPharma Inc. recorded a trading volume of 1.56 million shares. The stock ended the session 1.26% higher at $3.21. The Company's shares have gained 23.94% in the last month, 32.10% over the previous three months, and 51.42% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 22.69% and 37.55%, respectively. Moreover, shares of PDL BioPharma, which acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 74.46. Visit us today and download your complete report on PDLI for free at: http://dailystocktracker.com/registration/?symbol=PDLI

Progenics Pharmaceuticals 

New York-based Progenics Pharmaceuticals Inc.'s stock closed the day 4.55% higher at $6.44 with a total trading volume of 1.43 million shares, which was above their three months average volume of 995.72 thousand shares. The Company's shares have advanced 20.83% in the past month. The stock is trading above its 50-day moving averages by 3.36%. Additionally, shares of Progenics Pharma, which develops medicines and other technologies to target and treat cancer in the US and internationally, have an RSI of 55.57.  The complimentary research report on PGNX can be accessed at: http://dailystocktracker.com/registration/?symbol=PGNX

Agenus 

Shares in Lexington, Massachusetts headquartered Agenus Inc. recorded a trading volume of 887,760 shares. The stock ended yesterday's trading session 0.72% lower at $4.13. The Company's shares have advanced 18.68% in the past month and 17.66% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 0.68% and 4.55%, respectively. Furthermore, shares of Agenus, which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer, have an RSI of 60.19. Register for free on DailyStockTracker.com and download the research report on AGEN at: http://dailystocktracker.com/registration/?symbol=AGEN

Aptose Biosciences 

Mississauga, Canada headquartered Aptose Biosciences Inc.'s stock finished Monday's session 8.67% higher at $1.63 with a total trading volume of 844,015 shares, which was above their three months average volume of 385.85 thousand shares. The Company's shares have advanced 27.34% over the previous three months and 17.27% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 11.74% and 36.49%, respectively. Additionally, shares of Aptose Biosciences, which discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada, have an RSI of 62.33.

On September 07^th, 2017, research firm H.C. Wainwright upgraded the Company's stock rating from 'Neutral' to 'Buy' while revising its previous target price from $1 a share to $4 a share. Get free access to your research report on APTO at: http://dailystocktracker.com/registration/?symbol=APTO

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com